Cardio Catch-Up: Procyrion Raises Nearly $60M As Aortix Creeps Closer To Clinic

The Houston-based cardiovascular device developer has secured renewed support from its investors to fund its pivotal trial of Aortix, a device designed to treat patients suffering from often-fatal, difficult to treat cardiorenal syndrome.